Molecular mechanisms of osteosarcoma metastasis and possible treatment opportunities
Authors:
Open Access
- 1 May 2023
- journal article
- review article
- Published by Frontiers Media SA in Frontiers in Oncology
- Vol. 13
Abstract
In osteosarcoma patients, metastasis of the primary cancer is the leading cause of death. At present, management options to prevent metastasis are limited and non-curative. In this study, we review the current state of knowledge on the molecular mechanisms of metastasis and discuss promising new therapies to combat osteosarcoma metastasis. Genomic and epigenomic changes, metabolic reprogramming, transcription factors, dysregulation of physiologic pathways, and alterations to the tumor microenvironment are some of the changes reportedly involved in the regulation of osteosarcoma metastasis. Key factors within the tumor microenvironment include infiltrating lymphocytes, macrophages, cancer-associated fibroblasts, platelets, and extracellular components such as vesicles, proteins, and other secreted molecules. We conclude by discussing potential osteosarcoma-limiting agents and their clinical studies.Keywords
This publication has 101 references indexed in Scilit:
- Degalactotigonin, a Natural Compound from Solanum nigrum L., Inhibits Growth and Metastasis of Osteosarcoma through GSK3β Inactivation–Mediated Repression of the Hedgehog/Gli1 PathwayClinical Cancer Research, 2018
- Primary metastatic osteosarcoma: results of a prospective study in children given chemotherapy and interleukin-2Medical Oncology, 2017
- Pembrolizumab in advanced soft-tissue sarcoma and bone sarcoma (SARC028): a multicentre, two-cohort, single-arm, open-label, phase 2 trialThe Lancet Oncology, 2017
- BMTP-11 is active in preclinical models of human osteosarcoma and a candidate targeted drug for clinical translationProceedings of the National Academy of Sciences, 2017
- All-Trans Retinoic Acid Prevents Osteosarcoma Metastasis by Inhibiting M2 Polarization of Tumor-Associated MacrophagesCancer Immunology Research, 2017
- Wnt/β‐Catenin Signaling Activates Expression of the Bone‐Related Transcription Factor RUNX2 in Select Human Osteosarcoma Cell TypesJournal of Cellular Biochemistry, 2017
- A phase II study of clinical activity of SCH 717454 (robatumumab) in patients with relapsed osteosarcoma and Ewing sarcomaPediatric Blood & Cancer, 2016
- Phase I Clinical Trial of Ipilimumab in Pediatric Patients with Advanced Solid TumorsClinical Cancer Research, 2016
- Sorafenib and everolimus for patients with unresectable high-grade osteosarcoma progressing after standard treatment: a non-randomised phase 2 clinical trialThe Lancet Oncology, 2015
- The Role of RUNX2 in Osteosarcoma OncogenesisSarcoma, 2011